Discontinuation of sacubitril valsartan sodium tablets as directed by the physician is generally not dangerous. Sacubitril valsartan sodium tablets can be used to treat adult patients with chronic heart failure who have a reduced ejection fraction and can reduce the risk of cardiovascular death and hospitalization for heart failure. The drug is also able to replace angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists in combination with other heart failure treatment medications. When patients are treated with the medication, they may need to take it for a long period of time. If the disease has been gradually controlled or the body has recovered well, under the guidance of a specialized doctor to stop the drug, then generally does not pose a risk to the body. However, if the patient adjusts the medication without authorization, the discontinuation of the medication may cause the condition to worsen or induce other discomforts to the body, which may pose a certain danger to the body. Adverse reactions such as angioedema, hypotension, renal impairment, and hyperkalemia may occur during treatment with the drug. It is contraindicated in people who are allergic to the active ingredients of the product or any excipients. It is also contraindicated in patients with hereditary or sudden angioedema. Use or discontinuation of the drug should be under the supervision of a physician.